Acromegaly is a chronic and debilitating disorder associated with heightened mortality risk and multiple comorbidities. Appropriate multimodality therapy can normalize growth hormone (GH) and ...

Diagnosis Acromegaly and hyperprolactinemia caused by a mixed-cell adenoma, secreting growth hormone and prolactin. Management Trans-sphenoidal surgery followed by medical therapy with 20 mg ...

Acromegaly is often confused with gigantism, another rare condition that causes excessive growth as a result of high levels ...

The causes, symptoms, and treatment of acromegaly, a rare disease that causes your hands, feet, face, and other parts of your body to swell and grow too much.

Acromegaly and gigantism: An overview The overproduction of growth hormones causes excessive growth and changes in appearance. In children, this condition is called gigantism, and in adults, it is ...

Symptoms: Symptoms of acromegaly usually begin sometime after puberty, most commonly between the ages of 40 and 50.The disease causes a person's bones to enlarge — most notably, in the hands ...

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego ...

More than half of adults with acromegaly receiving the somatostatin receptor ligand pasireotide achieved normal insulin-like growth factor I levels, according to data from a long-term real-world ...

This method also was favored at the 6-month mark (69% controlled vs 47%, P=0.07), and patients achieved faster hormonal control with the personalized approached (320 days vs 365 days, P=0.010).

Crinetics is seeking to change the way acromegaly is treated. Ahead of its hopes for a 2025 U.S. drug launch, the biotech is looking to spread awareness about how to treat the condition. To that ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting ...